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INTRODUCTION 
 Diabetes mellitus is a metabolic disease of growing concern not only 
because of it's adverse effect on various metabolism of the body, but also 
because it puts the patient at higher risk of developing various macro and 
microvascular complications like cardiovascular disease (Ischaemic heart - 
disease), cerebrovascular disease, peripheral arterial disease, retinopathy, 
nephropathy, neuropathy etc. 
 Low serum magnesium has been proposed as a risk factor not only for 
the development of Diabetes mellitus but also has been linked to the emergence 
of it's various micro and macrovascular complications. 
 In some studies, diabetes mellitus has been found to lead to loss of 
magnesium in the urine, associated with glycosuria, which further lowers the 
magnesium in the plasma of Diabetic patients, aggravating the risk for 
development of it's complications. But various studies on human and animal 
model has given contradictory results regarding the association of low 
magnesium and various macro and microvascular complication of DM. 
 Since the prevalence of DM is found to increase very fast, the interest 
developed to determine the actual level of magnesium in Type 2 Diabetic 
Mellitus and it's complications, and to asscertain how far it correlates with the 
established biochemical parameter of this metabolic diseases and whether it's 
determination could be a helpful indicator in assessing the development and 
intensity of it's complications. 
 Hence with the above view this work "Evaluation of Serum  
Magnesium Level in Type 2 Diabetes Mellitus and it's Complications" has 
been taken up for the study. 
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MAGNESIUM 
 Magnesium is one of the most plentiful element on the earth. It occupies 
a position in group IIA in periodic table with atomic number 12 and atomic 
mass 24.31. 
 In vertebrates it is the fourth most abundant cation and the second most 
abundant intracellular cation1. 
 A healthy adult human body (70 kg) contains 25 gm of magnesium.  
SOURCES 
 Food items and beverges rich in magnesium are tabulated in Table No.1. 
 In addition, hard water is a substantial source of magnesium. Estimated 
daily intake of 2.3 mg and 5.21 mg of magnesium in subjects residing in soft 
and hard water areas respectively, have been reported, based on adults who 
consume 2 liter of water daily30. 
ABSORPTION 
 Magnesium is absorbed along the entire intestinal  tract, including large 
and small bowel, but the site for maximal magnesium absorption appears to be 
distal jejunum and ileum34,35,36 . Intestinal magnesium absorption is 30% to 
50% under normal dietary condition34,35,36. Absorption of magnesium is 
inversely proportional to the amount ingested37,38; for example 65% of 
magnesium is absorbed with an intake of 36 mg  versus only  11% absoprtion 
with an intake of 973 mg of magnesium39. 
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 There appears to be both an unsaturable passive  and saturable active 
transport system for magnesium absorption, which may account for higher 
fractional absorption at low dietary magnesium intake. 
Factors Influencing Magnesium Absorption 
 Factors enhancing and factors interfering magnesium absorption are 
given in Table No.2. 
DISTRIBUTION OF MAGNESIUM 
 Out of total 25 gms of magnesium present in adult human body, 53% is 
found in bones, 27% is found in muscle, 19.2% is found in soft tissues and 
0.8% is found in circulation. Out of 0.8% mg present in circulation, 0.5% is 
present inside the RBCs and 0.3% is present in the serum2,3,4,5. 
 Distribution of total magnesium in the body is given in Table No.3. 
 Magnesium occurs in higher concentration in intracellular compartment 
as compared to extracellular. Total intracellular magnesium concentration has 
been reported to range between 5-20 mM6,7, which is present either in free form 
or is combined with ATP. Only 0.5 to 5% of total intracellular magnesium is 
said to be present in free form depending upon the cell type and the means of 
measurement, the rest of it is combined with ATP8. 
 It has been found that, it is the free form of magnesium inside the cell, 
that is important for enzymatic actvity9,10. 
 Extracellular magnesium serves to maintain intracellular 
magnesium11,12,13. However, in the studies of Reinhart R.A. et al., Whang R. et 
al., Whang, R., Elin R.J., et al., Marx J.J. et al., Gunther, T, it has been found 
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that there is no good correlation between serum magnesium and intracellular 
magnesium level14,15,17-20.  
Various theories have been put forward to explain the magnesium 
transport inside and outside the cell. They are : 
1. Magnesium transport into and out of the cell takes place due to 
presence of carrier mediated transport system, possibly regulated 
by concentration of Mg++ within the cell20,21. 
2. The efflux of magnesium ion from cell appear to be coupled to 
sodium transport and requires energy22,23. Efflux of Mg++ is 
coupled to the movement of Na+ into the cell down to it's 
electrochemical gradient. Maintenance of this process requires 
the subsequent extrusion of Na+ by Na+ K+ ATPase. 
3. There is also evidence for a Na+ independent efflux of Mg++. 
4. Magnesium influx also appears to be linked to Na+ and HCO3- 
transport but by a different mechanism than efflux20,24.  
 Factors affecting magnesium transport into and out of the cells consist of 
pharmacological agents and harmones which are summarised below :- 
 Pharmacological agent like β-agonist is found to stimulate magnesium 
influx, but has no effect on it's efflux. Grubbs R.D. has stated that Epidermal 
Growth Factor increases magnesium transport into the vascular smooth muscle 
cell line25. 
 According to Lostroh A.J., et al., Krahl M.E., insulin and dextrose 
increases 28Mg uptake by a number of tissues including skeletal and cardiac 
muscle26.  
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 Kumar D; et al., Barbagallo M, et al., and Hwang D.L., et al., have all 
stated that insulin increases Mg++ in human red blood cells, platelets and 
lymphocytes27,28,29. 
 Both Type 1 and type 2 DM patients have low intracellular Mg level, 
because of lower level of insulin in former group and because of resistance of 
insulin action in the later group1. 
EXCRETION OF MAGNESIUM 
 The major excretory pathway for absorbed magnesium is through the 
kidney. The kidneys are the main organs of magnesium homeostasis in 
maintaining  plasma concentration. Only 3 to 6% of filtered load of magnesium 
in the kidney is excreted which works out to about 3.6 - 20.7 mg/day (3-17 meq 
day)11. Approximately 25-30% of filtered magnesium is reabsorbed in proximal 
tubule and 60-75% in ascending  limb of the loop of Henle43. Only about 2-5% 
is reabsorbed at the distal convoluted tubule. It is said that tubular secretion of 
magnesium does not occur155. 
 Reabsorption  of magnesium in distal tubule is load dependent. There is 
evidence for harmonal regulation of renal clearance of magnesium. 
Aldosterone and parathyroid harmone (PTH) are two harmones which 
influence magnesium excretion in urine. Aldosterone increases urinary 
excretion of magnesium. PTH has got negative feedback control in magnesium 
homeostasis. Hypomagnesemia enhances PTH secretion and PTH in turn 
enhances tubular reabsorption of magnesium156. Certain drugs are said to 
enhance the urinary loss of magnesium, a list of which is given in Table No.488. 
About 25 to 50 mg of endogenous magnesium may be excreted daily in 
faeces44. 
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 Magnesium may also be lost in the sweat, in amounts estimated at 
approximately 15 mg / day45. Though text book description of 0.9 mg per day 
loss is also available11.  
FUNCTIONS OF MAGNESIUM IN HUMAN BODY  
1. Role of Magnesium Present Intracellularly 
 Intracellular magnesium is important for over 300 different enzymes 
reactions either as a structural cofactor or an allosteric activator of enzyme 
activity45,52,53. 
 In ATP, magnesium binds to phosphate group, thereby forming a 
complex that assists in transfer of ATP phosphate. A list of magnesium 
dependent enzymes, their substrates and products are given in Table No.5. 
2. Role of Magnesium Present Extracellularly 
a) Extracellular magnesium serves as a source for maintaining 
intracellular magnesium9. 
b) Extracellular magnesium has also been shown to stabilize the 
nerve  axon. Lowering the serum magnesium concentration 
decreases the thresold of axonal stimulation and increases nerve 
conduction velocity. 
(c) Extracellular magnesium also influences release of 
neurotransmitters at neuromuscular junction by competitively 
inhibiting the entry of Ca++ in presynaptic nerve terminal. Low 
serum magnesium increases neuromuscular excitability. 
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3. Role of Magnesium Present in Bone  
 Nearly two  third of skeletal magnesium is incorporated into mineral 
lattice of the skeleton. About one third is elutable from bone and therefore 
exchangeable with ECF. It is this fraction of bone magnesium that is thought to 
serve as a reservoir for maintaining a normal concentration of magnesium in 
the plasma. 
4. Role of  Magnesium in Membrane Function 
 Magnesium is a cofactor for two active ion transport system across 
membranes requiring ATP, namely Na+ K+ ATPase and Ca++ ATPase162,163. 
5. Role of Magnesium on Insulin Secretion  
 Magnesium is a factor important for insulin secretion and insulin action. 
Magnesium depletion per se has been reported to impair insulin secretion and 
decrease peripheral insulin sensitivity143 and could contribute to diminished 
insulin effects. 
6. Role of Magnesium in Skeletal Muscle Function 
 Magnesium within muscle cell in said to interfere with the action of 
calcium, which is necessary for regulation of contraction and relaxation of the 
myofibril160. Effect on magnesium on muscle contraction, by interfering action 
of calcium can be explained as follows : 
1. Magnesium inhibits release of calcium from Sarcoplasmic 
Reticulum in response to increased influx of calcium from 
extracellular site, the effect which leads to relaxation of the 
myofibril160,161. 
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2. In addition, magnesium activates the Ca++ - ATPase pump of 
Sarcoplasmic Reticulum which decreases calcium concentration 
in the Sarcoplasm. 
3. Further, magnesium competes with calcium for specific binding 
sites on troponin C and myosin. Thus magnesium interferes with 
initiation of muscle contraction which is brought about by the 
binding of calcium to muscle protein157,159. 
 All the above effect of magnesium within the muscle cell causes 
a relaxation of the myofibril and decreases skeletal muscle tone 
and tension. 
7. Role of Magnesium in Smooth Muscle Contraction 
 Calcium binding in a smooth muscle cells initates Acetylcholine release 
and smooth muscle contraction. But magnesium binding to the calcium sites 
prevents calcium binding and inhibits contraction158. 
8. Role of Magnesium on Cardiovascular Functions 
a. Magnesium is said to inhibit - platelet adhesions and aggregation 
by stimulating the release of Prostacyclins from endothelium of 
blood vessels164,165. 
b. Magnesium reduces the likelihood of arrythmia by dilating the 
coronary arteries which enhances the perfusion of 
myocardium166,168. 
c. Magnesium decreases total and LDL cholesterol but increases 
HDL cholesterol169. That way plays a role in determining the 
luminal size of coronary vessles. 
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d. Extracellular and membrane bound magnesium in vascular 
smooth muscle cells, control and regulate the entry of calcium 
into the cells and it's binding and distribution within the cell170. It 
also stimulates the release of prostaglandins from the vascular 
endothelium171, as a result of which the tone, contractility and 
reactivity of vascular smooth muscle especially that of 
myocardial, renal, placental and cerebral vessels are influenced 
by magnesium172-174. 
9. Role of Magnesium on Blood Clotting 
 In blood coagulation, calcium and magnesium are antagonistic, with 
calcium promoting the clotting process and magnesium inhibiting it175. 
Reference range of serum magnesium in humans is given in Table No.6. 
EFFECTS DUE TO VARIATION IN THE LEVEL OF SERUM 
MAGNESIUM 
 Hypomagnesemia  
 Serum magnesium value less than 1.83 mg/dl (1.5 mEq/L) usually 
indicate magnesium deficiency37, 176-178. 
 Though magnesium content of peripheral lymphocyte is found to 
correlate with skeletal and cardiac muscle magnesium content, and it's 
measurement seems to be more accurate indicator of magnesium status than 
serum magnesium concentration;179-181 it is serum magnesium concentration, 
which is most available and commonly employed test to assess magnesium 
status in the body. 
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 In one study, Wong E.T. et al., have reported that approximately 10% of 
patients admitted to large city hospitals have Hypomagnesemia177.  
 In another study, Ryzen E. et al., reported 65% of the patients to be 
hypomagnesemic among ICU admissions181,182.  
Clinically apparent hypomagnesemia or magnesium depletion is usually 
due to loss of magnesium from either GIT or Kidney184. 
Causes for magnesium defeciency is enlisted in Table No.7.183 
Clinical sequelae of magnesium depletion : Frequent menifestations of 
moderate to severe magnesium defecieicny are shown in Table No.8. 
Hypermagnesemia  
 Wong E.T et al., who have observed as many as 10% of hospitalized 
patients to be hypomagnesemic, have also observed, as many as 12% of 
hospitalized patients to have mild or moderate elevation in Sr. magnesium 
concentration177. 
 Causes for hypermagnesium is enlisted in Table No.9. 
 The clinical menifestation at different level of hypermagnesemia is 
enlisted in Table No.10. 
RECOMMENDED DAILY ALLOWANCES  
RDA for various age groups in given in Table No.11. 
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DIABETES MELLITUS 
Defenition 
 Diabetes Mellitus is a group of metabolic disease which is characterized 
by hyperglycemia, resulting from defect in insulin secretion, insulin action or 
both55. 
Prevalence 
 Currently number of diabetic patients worldwide is estimated to be 
around 150 million, two third of which are residing in developing countries56. 
 This number is predicted to double by 2025, with the greatest number of 
cases in India and china alone57. 
Symptoms of Diabetes Mellitus 
 The classic symptoms of Diabetes Mellitus include Polyuria, Polydipsia, 
polyphagia and unexplained weight loss. 
Diagnosis of Diabetes Mellitus 
 American Diabetic Association (ADA), Criteria for diagnosis of 
Diabetes Mellitus are given in Table No.1255. 
 As per criteria of diagnosis of Diabetes Mellitus, since plasma glucose is 
elevated in this condition, it becomes essential to know it's homeostasis which 
is reviewed below :  
Glucose Homeostasis 
 Normal glucose homeostasis is tightly regulated by three interrelated 
processes :- 
 1. Glucose production in the liver 
 2. Uptake and utilization of glucose by peripheral tissue 
 3. Insulin secretion 
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1. Glucose Production in the liver : The liver of well fed persons 
actively synthesize glycogen and triacylglycerol, such a liver is glycogenic, 
glycolytic and lipogenic. In contrast, that of the fasting person is 
glycogenolytic, glyconeogenic, ketogenic and proteolytic. 
The liver is moved between these metabolic extremes by a variety of 
regulatory mechanisms : Substrate supply, allosteric effectors; covalent 
modification and induction - repression of enzymes58. 
2. Uptake and utilisation of glucose by peripheral tissues : 
Glucose transport into the cells is modulated by two families of proteins43 : 
 i. Intestinal sodium / glucose cotransporter 
 ii. Facilitative glucose transporters (GLUT) 
The intestinal sodium / glucose contransporter promote the uptake of 
glucose and galactose from the lumen of small bowel and their reabsorption 
from the urine in the kidney. The transporter uses the electrochemical Na 
gradient to transport glucose against it's concentration gradient. 
The second family of glucose carriers, termed facilitative glucose 
transporters (GLUT) is located on the surface of all cells. These transporters 
are designated GLUT-1 to GLUT-7.  
Distribution and function of these glucose transporters are enlisted in 
Table No.13. 
3. Insulin Secretion :  Insulin is a protein harmone secreted by β cells of 
islet of Langerhans' of the pancreas. It is the key harmone for regulation of 
blood glucose and generally normglycemia is maintained by balanced interplay 
between insulin secretion and insulin action.  
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CHEMISTRY OF INSULIN 
Human insulin has M.W. of 5,743 Da and consists of 51 aminoacids in 
two chains (A and B). These two chains are joined by two disulfide bridges, 
with a third disulfide bridge within the A chain. 
 In most species location of disulfide bridges are invariable and 
interchain  disulfide bridges connect `A'7 to `B'7 and `A'20 to `B'19.  Intrachain 
disulfide bridge connects residue 6 and 11 of the A chain. A chain have 21 
amino acids and B chain have 30 amino acids respectively43,46. 
SYNTHESIS OF INSULIN 
 Insulin is synthesized by ribosomes of rough endoplasmic reticulum of 
pancreatic β cells in it's precursor form "Preproinsulin", a protein which has 
M.W. of 11,500 Da. 
 Preproinsulin has 23 amino acids long pre, or leader sequence which 
directs the molecule into the cisternae of endoplasmic reticulum and then this 
sequence is removed to result in proinsulin molecule having M.W of 9,000 Da. 
 Proinsulin molecule provides the conformation necessary for proper 
disulfide bridges. It varies in length from 78 to 86 amino acids, with the 
variation occurring in the length of C-peptide region. 
 Proinsulin is stored in secretary granules in the golgi complex of the β 
cells, where protolytic cleavage to insulin and connecting peptide (C-peptide) 
occurs43. 
RELEASE OF INSULIN 
 Various factors stimulating and inhibiting the release of insulin is 
presented in Table No.14. 
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 Glucose is the most important stimulus for insulin release. Glucose 
elicits the release of insulin from pancreas in two phases. First phase begins 1 
or 2 minutes after IV injection of glucose and ends within 10 minutes. This 
phase represents rapid release of "stored" insulin. Second phase begins at the 
point where 1st phase ends. This phase depends upon continuing insulin 
synthesis and release and lasts until normoglycemia has been restored; usually 
within 60 to 120 minutes43. 
Mechanism of glucose induced release of `presynthesized (stored)' insulin 
 Glucose is taken up by pancreatic β cells via GLUT-2. Glucose is 
phosphorylated by glucokinase and further degradation leads to the formation 
of pyruvate. This pyruvate forms ATP in the mitochondria of β cells of 
pancreas. ATP is necessary for the delivery of energy needed for the release of 
insulin, but it is also involved in the cell membrane depolarization. The ADP / 
ATP ratio leads to activation of sulphonylurea receptor - 1 (SUR-1) protein, 
which leads to closure of the adjacent potassium channel [Potassium inward 
rectifier (KIR) 6.2 Channel]. Closure of KIR 6.2 channel will alter the 
membrane potential and open calcium channels, which triggers the release of 
`preformed' insulin form its storage granules51. 
Diagramatic Representation of abovesaid process has been depicted in 
Figure No.1. 
 Other agents including intestinal harmones (gastrin, secretin, GIT 
polypeptide) and certain amino acids (Leucine and Arginine) as well as 
sulfonylureas stimulate insulin release alone, but have no effect on insulin 
synthesis43.  
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Degradation  
 Liver is the major organ for insulin degradation. On the first pass 
through the portal circulation approximately 50% of the insulin is extracted by 
the liver where it is degraded. Kidney and placenta helps in additional 
degradation. Plasma half life of insulin is 3 - 5 minutes under normal 
conditions46. 
`Proteases' and `hepatic glutathione - insulin trans hydrogenases' are two 
enzyme system involved in insulin degradation. 
PHYSIOLOGICAL ACTION OF INSULIN 
A. EFFECT OF INSULIN ON GLUCOSE METABOLISM 
 a. Insulin effecting uptake of glucose 
 Insulin causes translocations of glucose transport protein (GLUTs) from 
the golgi apparatus to the plasma membrane, thus facilitating cellular uptake of 
glucose. 
 GLUT-4 present in striated muscle and adipose tissue is the major 
transprotein regulated by insulin46. 
 GLUT-2 which is present on hepatocyte, β cell of pancreas and 
basolateral membranes of intestinal and renal epithelial cells, are insulin 
independent. 
 b. Insulin effecting utilisation of glucose  
 Insulin favours the utilization as well as storage of glucose. Insulin 
favours glycolysis by increasing the activity and amount of several key 
glycolytic  enzymes (glucokinase, phosphofructokinase and pyruvate kinase). 
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 Dephosphorylation of glycogen synthase activates this enzyme and leads 
to increase glycogen synthesis. Insulin favours dephosphorylated  state of 
glycogen  synthase by activating phosphodiesterase which decreases cAMP 
level. So in presence of insulin glycogen synthesis is enhanced.  
 Insulin also inhibits glycogenolysis by favouring the inactivation of 
glycogen phosphorylase and inhibiting the glucose - 6 - phosphatase. 
 Gluconeogensis is inhibited by insulin by repressing the key enzymes, 
especially pyruvate carboxylase, phosphenol pyruvate carboxykinase and 
glucose - 6 - phosphatase. 
 Net effect is lowering of blood glucose level. 
B. EFFECT OF INSULIN ON LIPID METABOLISM 
 Insulin favours lipogensis, and inhibits lipolysis in adipose tissue. 
C. EFFECT OF INSULIN ON PROTEIN METABOLISM 
 Protein synthesis is favoured and catabolism is inhibited.  
MECHANISM OF ACTION OF INSULIN  
 Insulin action begins when this harmone binds to a specific glycoprotein 
receptor "Insulin receptor" on the surface of target cell. 
 The insulin receptor is a heterodimer consisting of two subunits, 
designated α and β,  in configuration α2 β2, linked by disulfide bond. α subunit 
is entirely extracellular, and it binds to insulin, probably by cysteine rich 
domain.  β - subunit is transmembrane protein that performs the second major 
function of a receptor i.e. signal transduction.  
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 Cytoplasmic portion of β subunit has tyrosine kinase activity and 
autophosphorylation site. Both of these are thought to be involved in signal 
transduction and insulin action. 
 Half life of  insulin receptor is 7 - 12 hours. Insulin receptors are found 
on most mammalian cells, in concentration of upto 20,000 per cell. When 
insulin binds to the receptor, several events occurs : 
 1. There is conformational change of the receptor 
 2. Receptors cross - link and form microaggregates  
 3. The receptor is internalized  
         & 
 4. One or more signals are generated 
 Various metabolic effects of insulin may be mediated by protein 
phosphorylation, dephosphorylation, effects on mRNA translation or affecting 
the gene expression. 
 Various Biochemical parameters useful in diagnosis and management of 
diabetes mellitus is given in Table No.15. 
Classification of DM : 
 Main types of DM are as follows55: 
 a. Type  1 (I) or Juvenile onset Diabetes : It occurs because of  β 
cell destruction, usually leading to absolute insulin defeciency  : 
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 It may be of two types : 
  i. Autoimmune type 
  ii. Idiopathic type 
 b. Type 2 (II) or adult onset Diabetes : This ranges from 
predominant insulin resistance, with relative insulin defeciency to a 
predominant insulin secretary defect, with or without insulin resistance.  
 Main feature for differentiation between there two groups is 
pathogenesis. Age of onset is not the criteria. 
 Other specific types of diabetes mellitus in given in Table No.16.55 
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PATHOGENESIS OF TYPE 2 DIABETES MELLITUS 
 The two metabolic defects that characterize type 2 diabetes mellitus 
are47 : 
 1. A derangement of insulin secretion due to β cell dysfunction and 
2. A decrease response of peripheral tissue to respond to the insulin 
(Insulin Resistance). 
 The metabolic defect leading to Type 2 DM are illustrated in Figure 
No.2. 
A. BETA  CELL  DYSFUNCTION 
 Early in the course of Type 2 diabetes, insulin secretion appears to be 
normal and plasma insulin level is not reduced. However, normal pulsatile, 
oscillating pattern of insulin secretion is lost and the rapid first phase of insulin 
secretion triggered by glucose is obtunded. It shows derangement in β cell 
responses to hyperglycemia early in Type 2 diabetes mellitus. 
Later in the course of Type 2 Diabetes Mellitus, a mild to moderate 
deficiency of insulin develops. Here irreversible β cell damage appears to be 
present, because of Glucose toxicity and, or Lipotoxicity. 
a. Glucose Toxicity :  The notion that hyperglycemia itself can 
decrease insulin secretion has led to concept of glucose toxicity, which implies 
the development of irreversible damage to cellular components of insulin 
production48,49.  
Reactive oxygen species (ROS) produced during oxidative glucose 
metabolism in β cells are normally detoxified by catalase and superoxide 
dismutase. β cells are equipped with a low amount of these proteins and also of 
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redox regulating enzyme glutathione peroxidase48.  Hyperglycemia leads to 
large amount of ROS in β cells, with subsequent damage to cellular 
components.  
b. Lipotoxicity : More recently the concept of lipotoxicity 
involving the β cells has been put forward51. There are several mechanism of 
lipotoxicity : 
1. According to Robertson R.P. et al., in the presence of glucose, 
fatty acid oxidation in β cells is inhibited and accumulation of 
long chain acyl coenzyme A occurs50. Long chain acyl coenzyme 
A can diminish the insulin secretary pathway by opening β cell K 
channel. 
2. A second mechanism might be increased expression of 
uncoupling protein - 2 in presence of acyl Co A, which could lead 
to reduced ATP formation and hence decreased insulin secretion. 
3. A third mechanism might involve apoptosis of β cell, probably 
via fatty acid or triacylglyserol induced ceramide synthesis, or 
generation of Nitric Oxide51. 
 Role of Islet Amyloid deposition in causing β cell dysfunction is 
controversial.  
B. INSULIN RESISTANCE 
 Insulin Resistance is said to be present when the biological effects of 
insulin are less than expected for both  
* Glucose disposal in skeletal muscle and  
* suppression of endogenous glucose production primarily in the 
liver59.  
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 Insulin Resistance may be due to a decrease in the number of insulin 
receptor or more importantly impairment in the postreceptor signalling of 
insulin receptors with or without decrease in the number of insulin receptors. 
MECHANISM OF INSULIN RESISTANCE  
i. Role of Phosphorylation and Dephosphorylation of Insulin 
receptor substrate (IRS) protein in Insulin Resistance  
Normally, after insulin binds to it's receptor, it leads to tyrosine 
phosphorylation of insulin receptor substrate (IRS) proteins which serve as 
binding scaffolds for various adaptor proteins and leads to the downstream 
signalling cascade60. 
In state of insulin resistance, the positive effects on downstream 
responses exerted by tyrosine phorsphorylation of the receptor and IRS proteins 
are opposed by dephosphorylation of these tyrosine side chains by cellular 
protein - tyrosine phosphatase and by protein phosphorylation on serine and 
threonine residue61. 
Phosphotyrosine phosphatase 1B is widely expressed and has important 
role in the negative regulation of insulin signalling62.  
Serine and threonine phosphorylation of IRS - 1 reduces it's ability to act 
as a substrate for tyrosine kinase activity of the insulin receptor and inhibits it's 
coupling to it's major downstream effector systems. 
Several IRS serine kinases have been identified, including various 
mitogen - activated protein kinases, C-Jun NH2 terminal kinase, atypical 
protein kinase C, and phosphatidylinositol 3' kinase60. 
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ii. Role of Adipocyte products and inflammation 
Increased concentration of NEFA and Inflammatory Cytokines (TNF-α, 
and IL-6) released by expanded adipose tissue adversly affects insulin 
signalling cascade63,64. 
NEFA inhibits insulin stimulated glucose metabolism in skeletal muscle 
and stimulate gluconeogenesis in liver65,66. 
 TNF-α enhances adipocyte lipolysis, which further increases NEFA, 
and also elicits it's own direct negative effects on insulin signalling pathway67. 
IL-6 inhibits the insulin signal by augmenting the expression of suppressor of 
cytokine signalling (SOCS) protein. SOCS family of proteins participate in IRS 
protein degradation through a ubiquitin - proteosomal pathway. 
iii. Adiponectin 
Whereas NEFA and several adipokines are increased in viseral obesity, 
the concentration of the adipose specific protein adiponectin are decreased, 
reducing it's insulin sensitizing effect in liver and muscles63,68.  
COMPLICATIONS OF TYPE 2 DIABETES MELLITUS  
 Complications of Type 2 Diabetes Mellitus have been classified in Table 
No.17. 
PATHOGENESIS OF DIABETIC COMPLICATIONS 
 Although clinical manifestations of diabetic complications 
(Microvascular / macrovascular) are very diverse, these syndromes share 
certain common pathophysiological charactersitics93.  
 Chronic tissue damage in diabetes is generally related to the severity and 
duration of Hyperglycemia, other determinants of specific complications 
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include genetic predisposition, obesity, hypertension  and dyslipidemia. Tissue 
damage may continue even after hyperglycemia has been improved 
(Hyperglycemia Memory93) 
ROLE OF HYPERGLYCEMIA IN DIABETIC COMPLICATIONS 
 The cause of most diabetic complications is probably prolonged 
exposure to high glucose level93. 
 DCCT (Diabetic Control and Complication Trial), UKPDS (United 
Kingdom Prospective Diabetic Study) and Kumamato Study all have supported 
the idea that chronic hyperglycemia plays a causative role in the pathogensis of 
diabetic microvascular complication. According to these studies there was a 
non significant trend in the incidence of macrovascular complication94. 
MECHANISM OF HYPERGLYCEMIA INDUCED DAMAGE 
 Four major hypothesis which are not mutually exclusive, have been 
proposed to explain how hyperglycemia might lead to the chronic complication 
of diabetes mellitus. They are93,94  : 
 A. Increased intracellular AGE formation 
 B. Increased polyol pathway 
 C. Increased protein kinase C activation 
 D. Increased hexosamine pathway. 
A. Increased intracellular AGE formation 
 One theory is that increased intracellular glucose leads to the formation 
of advanced glycosylation end products (AGEs) via the nonenzymatic 
glycosylation of intracellular proteins. Nonezymatic glycosylation is the 
process which occur physiologically. In this process glucose and other 
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glycating compound e.g. dicarbonyl such as 3-deoxy glucosone, methylglyoxal 
and glyoxal chemically attach to amino group and other long lasting molecule 
such as nucleic acid without aid of enzyme93,47. 
 These glycated protein undergo progressive dehydration, cyclization, 
oxidation and rearrangements to form AGE product95.  
 AGEs have been shown to cross link proteins (e.g. collagen, 
extracellular matrix proteins), accelerate atherosclerosis, promote glomerular 
dysfunction, reduce nitric oxide (NO) synthesis, induce endothelial dysfunction 
and alter extracellular matrix composition and structure94. 
 The formation of reversible and irreversible AGE is depicted in Fig.3. 
B. Increased Polyol Pathway Flux 
 A second theory is based on the observation that hyperglycemia 
increases glucose metabolism via sorbitol pathway. When intracellular glucose 
is increased, some glucose is converted to sorbitol by the enzyme aldose 
reductase. Several mechanism has been proposed to explain how 
hyperglycemia induced increase in polyol pathway flux could damage the 
tissue involved : 
 These include93 : 
 1. Sorbitol induced osmotic stress. 
 2. Decreased cytosolic Na+ / K+ ATPase activity. 
3. Reduced cytosolic NADPH (thus increased oxidative stress 
within the cell). 
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4. Increase in cytosolic ratio of NADH / NAD+, thereby inhibiting 
activity of the enzyme Glyseraldehyde- 3-Phosphate 
dehydrogenase (GAPDH) and thus increasing intracellular 
concentration of triose phosphate96.  Increased triose phosphate 
level could increase formation of both methylglyoxal, a highly 
active glycating compound and a precursor of AGE formation 
and (Via α-glycerol-3-phosphate) enhance production of DAG  
which activate protein kinase C. This polyol pathway which is 
normally inactive, and gets activated only when intracellular 
glucose level increases, has been depicted in Fig.No.4. 
C. Increased `Protein kinase C Activation' 
 Koya D.et al., Craven PA et al., and Shiba T et al., have all reported that 
enhanced de-novo synthesis of dicylglyserol (DAG), leads to persistent and 
excessive activation of protein kinase C (PKC). De-novo synthesis of DAG is 
enhanced within the cell, because of enhance glucose flux through the 
glycolytic pathway in conditions of increase intracellular glucose97,98,99. 
 In addition, Nishikawa T, et al., has proposed that increased cytosolic 
NADH / NAD+ associated with sorbitol oxidation to fructose and the inhibition 
of GAPDH by intracellular ROS generated in mitochondria could divert 
glysceraldehyde-3-PO4 away from the glycolytic route and towards production 
of dihydroxy  acetone phosphate (DHAP) and DAG100.  
 Further, Scivittaro V et al., have suggested that the enhanced activity of 
PKC enzyme could also result from the interaction between AGEs and their 
cell surface receptor101. 
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 Among other actions, PKC alters the transcription of gene for 
fibronectin, Type IV collagen, contractile protein and extra cellular matrix 
proteins in endothelial cells and neurons.  
D. Increase hexosamine pathway  
 Sayeski PP et al., Kolm Litty V et al., Daniels MC et al., all have 
proposed that hyperglycemia could cause diabetic complication by shunting 
glucose into the hexosamine pathway102,103,104. 
 Hence Fructose 6 - PO4 is diverted from glycolysis to form 
Glucosamine - 6 - PO4 which gets converted to UDP-N-acetyl glucosamine 
(UDP-Glc NAC) in the cytosol which can glycate transcription factors and thus 
enhance transcription of gene including plasminogen activator inhibitor -1 
(PAI-1) and transforming growth factor β1 (TGF - β1). The glucosamine 
pathway is illustrated in Fig. No.5. 
 The above four possible mechanism involved in the development of 
chronic complication of DM have been illustrated in Fig. No.6. 
 Other than the mechanisms elaborated above, the hypothesis of 
mitochondrial superoxide production and it's association with diabetes mellitus 
has also been postulated. 
Mitochondrial Superoxide Production : A unifying hypothesis 
 Nishikawa T. et al., has proposed the hypothesis that all four different 
pathogenic mechanisms described above can stem from a single hyperglycemia 
induced process, namely overproduction of superoxide by mitochondrial 
Electron Transport Chain (ETC)100. 
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 Wallace D.C. has supported this hypothesis via his experiment on 
cultured bovine aortic endothelial cells where he has observed that high 
glucose level increases ROS production inside the endothelial cells106. 
 Other than hyperglysemia the risk factors associated with development 
of diabetic complications are obesity, hypertension and dyslipidemia. 
Obesity 
 According to Mokdad AH et al., and Knowler WC et al., obesity is a 
common problem among diabetics. They have estimated that approximately 
60% of Type 2 diabetes mellitus patients are obese69,70. 
 The central distribution of fat and history of weight gain, in addition to 
body mass are independent risks of developing diabetic mellitus. Obesity in 
patients with Type 2 DM contributes to the development of complications like 
cardiovascular complications although the precise cause of increased 
cardiovascular morbidity and mortality in obesity is not known. According to 
Despres J.P. et al., obesity leads to development of  insulin resistance and 
hyperinsulinemia71. 
Hypertension 
 Barrett - Connor E. et al., Modon M. et al., Lesse GP et al., Skyler J.S. et 
al.,72,73,74,75, have all stated that diabetic patients have high blood pressure, 
independent of age or the presence of obesity or renal disease. 
 NHANES II data showed that hypertension is more than twice as 
prevalent among patients with type 2 DM than among those with normal 
glucose tolerance76. As per Krolewski A.S. et al., the prevalence of 
hypertension increases with the duration of diabetic mellitus77. 
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  Several studies have demonstrated that hypertension is a significant risk 
factor for the development of vascular disease in individual with diabetic 
mellitus78. According to Kuller LH et al., Tuck M.L. et al., hypertension is a 
prime risk factor for development of cardiovascular disease, cerebrovascular 
disease and  peripheral vascular disease, when accompanies diabetes.  
Dyslipidemia 
 Abnormalities of plasma lipid and lipoprotein metabolism - like 
hypertriglyseridemia, decrease HDL concentration, increase total cholesterol 
and decrease LDL cholesterol concentration are very common in diabetes and 
have long been thought to increase cardiovascular risk as they do in 
nondiabetic state.  
DM not only changes lipoprotein concentration but also induces a 
number of alteration in lipoprotein composition that may influence 
atherosclerosis process; and may lead to macrovascular complications.  
Small, dense LDL particles which is a form of LDL, is found to be 
associated with not only insulin resistance syndrome81, but also has been 
demonstrated to be more susceptible to glycation and oxidation. 
Apo B of LDL is glycated82 and these glycated LDL is taken up by 
macrophages to form Foam cells. Not only glycation, but oxidation of LDL 
also is believed to play an important role in atherogenesis. Hunt J.V. et al., 
have shown that glycated LDL is more susceptible to oxidation83. 
Oxidation of LDL leads not only to increased foam cell formation84,85, 
but also increases adhesion of monocyte to endothelial cells. 
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It is also said that oxidised LDL also stimulates monocyte chemotaxis, 
and can be directly toxic to endothelial cells86. 
In addition, Lopes Virella MF et al., have shown that modified 
Lipoprotein species can be immunogenic and circulating immune complex may 
accelerate atherosclerosis87.  
Diabetic individuals have smaller proportion of HDL-2 subfraction and 
greater proportions of HDL-3, a distribution which is associated with 
atherosclerosis78. 
Other factors associated with Atherosclerosis in DM 
 1. Glycation of other protein like collagen. 
 2. Endothelial dysfunction : Nitric oxide (NO) synthase is 
endothelium derived and is the key regulator of vascular tone. According to 
Sobrevia L et al. NO  synthase is impaired in DM89. 
Mortality is Diabetic Patients92 
 Death is usually due to complications in DM. The causes of death in 
diabetic patients in India and developed countries have been depicted in Figure 
No.7. 
 Having elaborated about the various complications of DM and the 
mechanism involved in pathogenesis of these complications, review on the 
complications micro and macrovascular, taken up for the study namely diabetic 
retinopathy, diabetic nephropathy, diabetic coronary atherosclerosis and 
diabetic peripheral vascular disease is as follows : 
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DIABETIC RETINOPATHY 
 Diabetic Retinopathy is a significant cause of blindness in diabetic 
patients. 
 Klein R. et al., in their population based study `Wincosin Epidemiologic 
study of diabetic  retinopathy (WESDR) have stated that among type 2 DM 
patients suffering from the condition for less than 5 years duration, have  
retinopathy in 40% of the patient taking insulin and in 24% of the patient not 
on insulin therapy111. 
 These rates increased to 84% and 53% respectively when the duration of 
diabetes mellitus increased to 15 - 19 years111. 
 Classification of diabetic  retinopathy is based in general on the severity 
of intraretinal microvascular changes and the presence or absence of retinal 
neovascularization. 
 Classification of diabetic retinopathy as presented by "Diabetic  
Retinopathy Study Research Group have been given in Table No.18. 
 The pathophysiological mechanism involved in non- proliferative 
diabetic retinopathy (NPDR) includes loss of retinal pericytes, increased retinal 
vascular permeability, alteration in retinal blood flow, and abnormal retinal 
microvasculature, all of which lead to retinal ischaemia. 
 Neovascularization in response to retinal ischaemia is the hallmark of 
proliferative diabetic retinopathy (PDR). These new vessels rupture easily 
leading to vitreous haemorrhage, fibrosis and ultimately retinal detachment94. 
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RISK FACTORS FOR PROGRESSION OF DIABETIC 
RETINOPATHY. 
1. Glycemic control : It has been found that the level of glycemic 
control is inversly proportional to the severity of diabetic  retinopathy. Klein R. 
et al., Lloyd CE et al., Teuscher A. et al., have demonstrated that increased 
severity of diabetic retinopathy is associated with poor glycemia 
control112,113,114. 
 DCCT (Diabetic Control and Complication Trial) have shown that the 
patients having HbA1c of 10% have five fold greater risk of developing diabetic 
retinopathy as compared to the patients having 7% of HbA1c110. 
 Epidemiological analysis of the UKPDS (United Kingdom Prospective 
Diabetic Study) data showed a continuous relationship between the risk of 
microvascular complication and glycemia, such that for every percentage point 
decrease in HbA1c (e.g. 9% to 8%), there was a 35% reduction in the risk of 
microvascular complication110. 
2. Hypertension : UKPDS has shown that intensive blood pressure 
control was associated with decreased risk of retinopathy progression.  
Chaturvedi N. et al., in their study of `Blood  Pressure Medication In 
Diabetic Retinopathy' have shown that there might be a specific benefit of 
Angiotensin converting enzyme (ACE) inhibition and blood pressure reduction, 
even in normotensive people, on the progression of diabetic  retinopathy115. 
3. Elevated Sr. Lipid Levels :  Increased total cholesterol and 
triglyseride were found to be associated with diabetic  retinopathy. Chew E.Y 
et al., in ETDRS research and Klein B.E.K. et al., in WESDR (Wilconsin 
Epidemiologic study of Diabetic Retinopathy) have stated that elevated levels 
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of Sr.Cholesterol were associated with increased severity of retinal hard 
excudate116,117. Elevated Sr.TAG level were also associated with a greater risk 
for development of high risk proliferative diabetic retinopathy in ETDRS 
patients185. 
In a study in Pittsburg, elevated TAG and elevated LDL cholesterol 
were found to be associated with proliferative diabetic  retinopathy186. 
Pathogensis of Early Diabetic  Retinopathy 
 The pathway involved in the pathogenesis are the following. 
1. Polyol pathway : Hyperglycemia leads to excessive production 
and accumulation of polyol, which has been shown to be important in the 
development of tissue in the lens and optic nerve187,188. 
 Animal experiments suggest that an aldose reductase inhibitor could 
slow the development of diabetic  retinopathy189,190. 
 But, clinical trials in patient with type 2 diabetic  mellitus have not yet 
demonstrated any retardation of progression of retinopathy, after administering 
aldose reeducates inhibitor "Sorbinil"105,191. 
 2. Non Enzymatic Glycation : Non enzymatic glycation of 
proteins and DNA occurs during hyperglycemia, potentially altering enzyme 
activity and DNA integrity. This results in excessive cross - linking of 
proteins90. 
 Aminoguanidine inhibits formation of AGE and has been reported to 
decrease the effects of diabetic  mellitus on retinal blood flow, permeability, 
and other microvascular parameters in diabetic rats91. 
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3. Protein kinase C : During period of hyperglycemia, PKC 
activity increase in the retina and retinal endothelial cell. PKC is known to 
affect vascular permeability, contractility and basement membrane synthesis 
and vascular cell proliferation. 
RETINOPATHY SCREENING 
 According to the guidelines given by `American Diabetic Association' 
(ADA), scheme for retinopathy screening in diabetic population is as follows. 
Patients with Type 1 diabetes mellitus should have an initial dilated and 
comprehensive eye examinations by an ophthalmologist or optometrist within 5 
years after the onset of diabetes mellitus. 
 Patient with Type 2 diabetes mellitus should have initial and 
comphrensive eye examination by an ophthalmologist or optometrist shortly 
after diagnosis of diabetes mellitus followed by subsequent annual 
examination.  
 If eye is found to be normal during initial examination, follow up 
examination can be less frequent120. 
DIABETIC NEPHROPATHY 
 Diabetic nephropathy is major cause of diabetes mellitus related 
morbidity and mortality51. It is the leading cause of chronic kidney diseases in 
patients starting renal replacement therpay107. 
 Diabetic nephropathy has been classically defined by the presence of 
proteinuria, >0.5 g/24 hr. This stage is referred to as overt nephropathy / 
clinical nephropathy / proteinuria or macroalbuminuria. 
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 Incipient stage of diabetic nephropathy is when the albumin excretion in 
the urine is very less i.e. <300mg / 24 hr. This is  termed as microalbuminuria. 
The cutoff values adopted by the American Diabetes Association (timed, 
24-h, and spot urine collection, for the diagnosis of micro and 
macroalbuminuria depicted in Table  No.19. 
In one study, only 30 - 45% of microalbuminuric patient have been 
reported to progress to proteinuria over 10 years108. 
 Diabetic nephropathy develops at the most in 40% of patients with 
diabetes, even when high glucose levels are maintained for long period of time. 
This observation raised the concept that only a subset of patients have an 
increased susceptibility of diabetic nephropathy. Genetic susceptibility 
contributes to the development of diabetic nephropathy in patients with both 
type 1 and type 2 diabetes mellitus. 
 In addition to `hyperglycemia', `hemodynamic insults' and 
`proteinuria' perse has been identified as major mediator of renal damage in 
diabetics109. 
 Figure No. 8, illustrates the mechanism of diabetic nephropathy. 
Role of Hypertension in diabetic kidney damage 
  Hypertension plays a critical role in the progression of diabetic 
nephropathy. Levels of blood pressure closely related to the rate of decline in 
GFR95. 
 Hyperglycemia induces vasodilatation with a marked decrease in 
afferent and to a lesser reduction in efferent arteriolar resistance. This leads to 
an increase in Glomerular capillary pressure levels and allows ready 
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transmission of any increase in systemic blood pressure to glomerular capillary 
circulation95. 
 Increased intraglomerular pressure through increased mechanical stress 
and shear forces may damage the endothelial surface and disrupt the normal 
structure of glomerular barrier, eventually leading to mesangial proliferation, 
increased ECM production and thickening of glomerular basement membrane. 
These haemodynamic abnormality usually are associated with hypertrophic 
changes in the glomerulus. 
Role of Proteinuria 
 Proteinuria of diabetic nephropathy is not only a complication of this 
disease but also a factor involved in it's pathogenesis. 
 Excessive tubular reabsorption of protein and the consequent 
accumulation of protein in tubular epithelial cells induces the release of 
vasoactive and inflammatory mediators, such as, TGF-β, endothelin - 1, 
osteopontin and macrophage chemotactic protein - 1. 
 These factors in turn lead to infiltration of mononuclear cells, causing 
injury to the tubulo-interstitium and ultimately renal scarring and 
insufficiency109. 
 A vicious cycle is then established in which changes in renal 
hemodynamics  either primary or in response to nephron loss induce further 
proteinuria, perpetuating a mechanism of interstitial scarring and progressive 
renal impairment. 
Screening for diabetic nephropathy 
Screening for diabetic nephropathy must be initiated at the time of 
diagnosis in patients with type 2 diabetes mellitus118, since ~7% of them 
already have microalbuminuria at that time119. 
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 For Type I diabetes mellitus, first screening has been recommended at 5 
years of diagnosis118. 
 If microalbuminuria is absent, the screening must be repeated annually 
for both type 1 and type 2 diabetic patients118. 
 As per guidelines of American Diabetes Association, the first step in the 
screening and diagnosis of diabetic nephropathy is to measure albumin in the 
spot urine sample, collected either as the first urine in the  morning or at 
random, for example at the medical visit118. The results of albumin 
measurements in spot collection may be expressed as urinary albumin 
concentration (mg/dl) or as urine albumin to creatinine ratio (mg/g or 
mg/mmol).  
MACRO VASCULAR COMPLICATION 
CARDIOVASCULAR DISEASE 
 Cardiovascular disease is a prevalent and detrimental complication of 
diabetes mellitus.  
 Several observations highlight the high prevalence of cardiovascular 
disease in diabetes and the gravity of cardiovascular events in diabetic 
population. 
 According to Stamler J. et al.,  age-adjusted cardiovascular mortality is 
at least 2 fold higher in diabetic men than in nondiabetic subjects in the 
presence of any number of major risk factors121.  Sprafka JM, et al., have stated 
the survival after MI is worse in diabetic men and women122. Haffuer SM et al., 
have found  in their study that incidence of death from cardiovascular causes in 
diabetic subjects without a history of MI during 7 years follow up, was similar 
to the incidence observed in nondiabetic subjects with a history of MI123. 
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 Anderson AJ et al., and Quigley PJ et al., have shown that diabetic 
patients have greater occlusion of coronary arteries and a greater prevalence of 
multivessel disease124,125. 
 Mooradian AD et al., and Thurman JE et al., have mentioned various 
factors which contribute accelerated atherosclerosis in diabetes mellitus126,127. 
These factors include excess prevalence of traditional risks such as Obesity, 
hypertension and dyslipidemia along with modification of lipoproteins and 
other key protein with glycation and oxidation, increased procoagulation and 
possibly the state of insulin resistance.  
PERIPHERAL ARTERIAL DISEASE (PAD) 
 Peripheral arterial disease is most commonly a manifestation of systemic 
atherosclerosis in which the arterial lumen of the lower extremities become 
progressively occluded by atherosclerotic plaque128. It is a progressive 
condition, which may be symptomatic or asymptomatic. 
 Number of asymptomatic patients are found to be more as compared to 
the number of symptomatic patients129. 
 Symptoms of PAD ranges in severity from intermittent claudication, 
(Pain relieved at rest) to critical limb ischemia (Pain at rest). Critical limb 
ischaemia if untreated, can lead to nonhealing wounds, gangrene, and eventual 
amputation.  
 Ongoing "Prevention of Progression of Arterial disease and Diabetes 
(POPADAD) study has demonstrated that 20% of the diabetic patients had, 
Ankle Brachial Index (ABI) value less than 0.91, which is clinically indicative 
of PAD130. 
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 Elhadal TA et al., in their study on diabetic population have found that 
50% of diabetic patients were having PAD130. 
 According to Hirsch AT et al., Elhadd TA et al., Murabito JM et al., 
advanced age, smoking and diabetes mellitus are strongly associated with 
PAD130,131,132. 
 PAD is a powerful indicator of systemic atherosclerosis. According to 
one study conducted by Criqui, ME, et al., regardless of whether symptoms are 
evident, patients with PAD have an increased risk of subsequent MI and stoke 
and are 6 time more likely to die within 10 years than patient without PAD133. 
 Type 2 DM patients with foot ulceration have macrovascular disease 
which impair skin oxygenation in such subjects. In absence of macrovascular 
disease, impaired nerve function may be associated with foot ulceration in 
Type 2 DM. 
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MAGNESIUM IN TYPE 2 DIABETES MELLITUS AND IT'S 
COMPLICATIONS : THEIR RELATION 
 Magnesium deficiency has been associated with many chronic diseases. 
Diabetes mellitus is one of them136. Gunn I.R. et al., Mather H.M. et al., have 
found upto 39% of out patient diabetics to be hypomagnesemic134,135 while 
Tosiello found that nearly 25% of their diabetic outpatients were 
hypomagnesemic137 . Low dietary intake of magnesium and loss of magnesium 
in urine via osmotic diuresis have been suggested as an explanation for lower 
level of magnesium in diabetic group. Lopez - Ridaura .R. et al., in their follow 
up study found that there was a significant inverse association between 
magnesium intake and diabetes mellitus risk138. Driziene Z et al., found that 
diurnal, overnight and 24 hrs, magnesium urinary excretion were significantly 
higher in diabetic subjects as compared to non-diabetic healthy subjects139. 
 Wang J.L. et al have found in their study conducted in Thaiwan that 
there was an inverse association between plasma magnesium concentration and 
prevalence of diabetes mellitus.  The risk of diabetes mellitus was elevated 3.25 
times at plasma magnesium level < 0.863 mmol/L. Contrary to other studies 
they found that there is no association between diabetes and low dietary 
magnesium140. 
 Low serum magnesium has shown to play an important role in 
pathogenesis of Insulin resistance. According to McCarty MF141 magnesium 
can function as a mild, natural calcium antagonist. So in magnesium deficiency  
there is increased level of intracellular Calcium. This increased intracellular 
calcium  may compromise the insulin responsiveness of adipocytes and skeletal 
muscles leading to insulin resistance141. 
 Takaya J. et al., have suggested that magnesium is required for both 
proper glucose utilization and insulin signaling. Metabolic alteration in cellular 
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magnesium, which may play the role of a second messenger for insulin action, 
contribute to insulin resistance .142. 
 Paolisso G. et al., Sgogran A et al., Nadder, J. et al., have reported that 
magnesium depletion perse impair insulin secretion and decreases peripheral 
insulin sensitivity and could contribute to diminished insulin effects143,144,145. 
Magnesium in Atherosclerotic Vascular Disease 
 Vitale J.J., et al., saw that experimental magnesium depletion is 
characterized by hypertriglyceridemia and hypercholesterolemia as well as 
atherosclerosis146. Serum concentration. of VLDL and LDL are elevated, 
whereas HDL is decreased.  Decreased lipoprotein lipase activity as well as 
decreased lecithin cholesterol acyltransferase activity may be responsible for 
hyperlipidemia.147. 
 This adverse lipid profile in hypomagnesemia  is a strong risk factor for 
developing atherosclerosis. 
 Anetor JI et al., in their study on Nigerian population have found that 
type 2 diabetes mellitus patients have decreased serum magnesium level, 
probably suggesting lower antioxidant status in this condition. This may lead to 
greater chances of LDL-cholesterol oxidation, which is turn increases chances 
of Atherosclerosis148. 
Effect of Magnesium on vasculature and platelet function               
 In addition to increasing the likelihood of developing atherosclerosis, 
hypomagnesemia leads to increased platelet reactivity  and vasospasm which is 
thought to be involved in genesis of  myocardial infraction in 
hypomagnesaemia. 
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 There are several theories for the mechanism of increased platelet 
reactivity and vasospasticity in hypomagnesaemia.  
1. According to Altura B.M et al., hypomagnesaemia causes increased 
intracellular Ca++.  Increased intracellur calcium is cruicial  for smooth 
muscle contraction and platelet - aggregation. So hypomagnesaemia 
increases smooth muscle contraction and platelet - aggregation151. 
2. Nadler J et al suggested that magnesium may be related to inhibition of 
the synthesis of thromboxane A2 and 12 HETE, eicosanoids thought to 
be involved in platelet aggregation152,153. So in magnesium depletion 
these eicosanoids are synthesized in increased amount leading to platelet 
aggregation. 
 They also suggested that magnesium stimulate synthesis of PGI2, so in 
deficiency of magnesium PGI2 is not synthesized.  
 Above mechanism leads to increased vasospasmability of coronary 
artery and could play a role of the onset of IHD. 
So, the lower serum magnesium in diabetic patients may be a 
explanation for the higher incidence of macrovascular complications 
like cardiovascular atherosclerosis and peripheral arterial disease is such 
patients.  
Magnesium in peripheral vascular disease  
 Rodriguez - Moran et al found in their study that serum magnesium 
depletion is present and shows a strong relationship with fool - ulcers in 
subjects with Type 2 diabetes mellitus and foot - ulcers.149.  
 
 42
Magnesium in retinopathy 
 Several contradictory reports are available regarding level of magnesium 
in microvascular complications of diabetes like diabetic retinopathy. 
Harold et al., have found that patients with retinopathy have a lower 
mean plasma magnesium concentration  than patients without retinopathy.            
While according to Sheehan JP. the role of magnesium deficiency in 
microvascular complication has not yet been proved150.             
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AIM OF THE STUDY 
 On reviewing the mineral magnesium and it's association with diabetes 
mellitus and various macro and microvascular complications of this disease, it 
was decided to analyse the above mineral in Type 2 diabetes mellitus and some 
of the complications of the disease with the following aim : 
1. To determine the reference range of Sr.Mg for the study. 
2. To determine the level of Sr.Mg in diabetes mellitus type 2 and to 
analyse whether it varied from the above reference range. 
3. To determine the level of Sr.Mg in diabetic complications namely 
diabetic retinopathy, diabetic nephropathy, coronary  
atherosclerosis, and peripheral vascular disease and to analyse 
whether in these complications it varied from the reference range 
or from the corresponding level in Type 2 diabetes mellitus 
without any complication. 
4. To correlate the level of Sr.Mg in the above conditions with the 
level of degree of control as determined by HbA1c in Diabetes 
mellitus.  
5. To determine whether a cutoff level for Sr.Mg can be obtained 
between apparently normal individuals and diabetics and between 
the latter level and the corresponding level in it's complications. 
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MATERIALS AND METHODS 
This study was undertaken with the aim to determine Sr.Mg level in 
patients with Type 2 Diabetes Mellitus without it's associated complications 
and Type 2 Diabetes mellitus patients with it's various macro and micro 
vascular complications namely Coronary atherosclerosis, Peripheral vascular 
disease (Foot ulcer) and retinopathy, nephropathy respectively. 
The study was conducted at Government General Hospital, Chennai on 
total of 120 subjects of age group 40 - 70 years; of whom 20 were apparently 
healthy and served as control. 20 apparently healthy subjects were formed of 
10 male and 10 female. They were grouped as Category (1). Remaining 100 
subjects  formed the study group. The study group was constituted by 20 
patients (10 male and 10 female) in each of the following categories. 
Category 2 - Type 2 DM without it's associated complication. 
Category 3 - Type 2 DM with coronary Atherosclerosis 
Category 4 - Type 2 DM with peripheral vascular diseases  
(foot ulcer) 
 Category 5 - Type 2 DM with Retinopathy 
 Category 6 - Type 2 DM with Nephropathy 
 
 For the control group (category 1) the apparently healthy adults of 40 - 
70 years were selected from staff of Madras Medical College and their 
relatives.  
For category 2 (Type 2 DM  without any of it's associated complication) 
patients were selected from outpatients clinic of Diabetology Department at 
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Government General Hospital, Chennai who came there for monitoring of 
Type 2 DM and treatment. They were diagnosed as having DM - Type 2 based 
on American Diabetic Association criteria of fasting hyperglycemia of ≥ 126 
mg/dl after an overnight fast of 8 hours. 
Those with inconsistent values of fasting glucose (110 mg/dl - 126 
mg/dl) were diagnosed on the basis of OGTT. (WHO Criteria). 
For Category 3 (Type 2 DM with coronary atherosclerosis) patients 
were selected from inpatients of Department of Diabetology, Department of 
Cardiology as well as from outpatient clinic of Department of Diabetology, 
GGH, Chennai. Diagnosis of coronary atherosclerosis was based on coronary. 
angiogram. 
For Category 4 (Type 2 DM with Peripheral Vascular Disease) patients 
were selected from wards as well as from outpatient clinic of Department of 
Diabetology, GGH, Chennai, where they presented as foot - ulcer. Foot ulcer 
because of neuropathy was ruled out by history, clinical examination, 
`monofilament study' and `biothesiometry'. 
For Category 5 (Type 2DM with Retinopathy) patients were selected 
from wards as well as from outpatient clinic of Department of Diabetology, 
GGH, Chennai. Diagnosis was based on Fundoscopic finding. NPDR and PDR 
both were included in the study. 
For Category 6 (Type 2 DM with nephropathy) patients were selected 
from wards of Department of Diabetology, Govt. General Hospital, Chennai. 
Diagnosis of nephropathy was based on 24-hour urinary protein. Excretion of 
more than 500 mg / day of total protein in the 24 hours urine in diabetic 
patients were considered to be because of nephropathy.  
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Patients having more than one complication together  (eg Type 2 DM 
with coronary atherosclerosis as well as retinopathy) were grouped under both 
the categories respectively. 
 While selecting subjects for the study group, following inclusion and 
exclusion criteria was adopted. 
 
Inclusion Criteria Exclusion Criteria 
Consent Recent H/o Diarrhoea, vomiting, 
 Recent H/o Parentral fluid therapy 
 
Age 40 - 70 yrs 
Patient on drugs causing urinary loss 
of Mg e.g. Frusemide, Thiazide, 
diuretics. 
 Alcoholic patients were not included 
in the study, as ethanol causes loss of 
Mg in the urine 
 Smokers were not  included in the 
study 
 
 For all the 120 subjects, 6 ml of peripheral venous blood was drawn 
under aseptic precaution from the anticubital vein, drawn blood was divided 
into 3 tubes as given below. Utmost care was taken to prevent hemolysis during 
the above procedure. 
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 Anticoagulant 
Amount 
of Blood 
(ml) 
Investigations 
performed 
Eppendorff's 
Tube 
EDTA 0.5 HbA1c 
Test Tube 1 NaF : Potassium 
Oxalate (1:3) 
1.5 Pl- Glucose 
Test Tube 2 Plane (Acid 
washed) 
4 Serum - Magnesium 
Blood urea  
Sr- Creatinine 
 
 Blood in Test Tube 2 (Plane) was allowed to stand for one hour and 
Serum was separated by centrifugation after retraction of clot. 
 The separated serum was divided into 2 parts 0.5ml of serum was stored 
in clean, acid washed, dried eppendorff's tube at   - 20°C, which was used for 
Sr.Mg estimation within 3 weeks of collection. 
 Remaining  serum was utilised for estimation of parameters namely  Bl -
urea and Sr. Creatinine on the same day of collection. 
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ESTIMATION  OF SERUM MAGNESIUM 
Methodology 
 Sr.Magnesium was estimated using atomic absorption 
spectrophotometer in the Department of Animal Nutrition, Madras Veterinary 
College, Chennai. 
Instrument 
 Atomic absorption spectrophotometer . " Model 3110 Perkin - Elmer". 
Principle 
  Atomic absorption spectrophotmetry is based on the principle of 
absorption spectrophotometry. Here element to be analysed is dissociated from 
it's chemical bonds and placed in an unexcited or ground state (neutral atom). 
The ground state atom is capable of absorbing radiation at a very narrow 
bandwidth corresponding to it's own line spectrum. A hollow cathode lamp 
with the cathode made of the material to be analysed is used to produce a 
wavelength of light specific for the material. When the light from the hollow 
cathode lamp enters the flame, some of it is absorbed by the ground state atom 
in the flame, resulting in a net decrease in the intensity of the beam from the 
lamp. This process is referred to as atomic absorption.  
Standarization of Instrument 
Instrument was set using parameters given in Table No.20. 
Accuracy of instrument was checked using working standard of 
concentration of 0.3 mg/dL. Working standard was prepared from stock 
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standard solution. Stock standard solution consisted of 1000 mg per litre of 
magnesium nitrate in nitric acid.  
PROCEDURE  
Serum sample was diluted one in ten using deionized water and reading 
was taken. 
Final concentration  of the sample was calculated using following  
equation. 
     
Concentration in    Value in ppm x Dilution factor(10) 
mg/dL  =        ____________________________   x 100 
    
                106  
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ESTIMATION OF HbA1C 
Methodology 
 Cation - exchange Resin method was utilised for estimation of HbA1C 
using "Monozyme's Glycohemin Kit". 
Principle 
 Monozyme glycohemin kit is based upon the property of 
nonglycosylated hemoglobin to bind with a weak cation exchange resin leaving 
Glycated Haemoglobin (HbA1) free in the supernatant. 
 Elimination of the labile schiff's base was achieved during hamolysis. 
The hemolysate is then mixed with a weakly binding cation exchange resin. 
The nonglycosylated haemoglobin binds to the resin leaving Glycated 
Haemoglobin free in the supernatant. The Glycated Haemoglobin percentage is 
determined by measuring the absorbance of Glycated Haemoglobin fraction 
and of the total Hb at 415 nm. This Glycated Haemoglobin constituted of 
HbA1a + HbA1b + HbA1c . Value of HbA1c  is obtained from the value of HbA1 
from conversion table given in Table No.21. 
Normal Range of HbA1c  
 4.4 - 6.4%  
Reagents and Consumable 
 Prefilled resin tubes - 10 x 2 ml 
 Lysing reagent  - 5 ml 
 Resin separators - 10 Nos 
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Procedure 
Step 1 - Hemolysate Preparation 
250 µl lysing reagent was dispensed into required number of labeled 
tubes for different samples. 50µl of the well - mixed whole blood sample was 
placed into the appropriately labeled tube and mixed well. It was incubated for 
5 minutes at room temperature to allow complete lysis of R.B.C. 
Step 2 -  Glycohemoglobin fraction separation 
100 µl each of the hemolysates from the step 1 was added into 
respective resin tubes. Resin separator was inserted into each tube so that the 
rubber sleeve is approximately 1 cm above the liquid suspension of the resin. 
Tubes were placed on the rocker or rotator and mixed continuously atleast for 5 
minutes. (Binding of nonglycosylated hemoglobin fraction to the resin requires 
atleast 5 minutes time).  After this resin separator was pushed into the tubes 
until the resin is firmly packed to allow the supernatant to come into resin 
separator tube. Supernatant was directly aspirated into semiautoanalyser and 
reading was taken against distilled water at 415 nm. 
Step 3 - Total hemoglobin fraction 
5.0 ml of deionized water was dispensed into required number of 
properly labeled tubes. 20µl of each hemolysate  from step I was added to the 
above tubes and mixed properly. Absorbance was read against distilled water at 
415 nm. 
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Calculations 
 Results for the unknown samples were calculated as follows: 
  Absorbance of Glycohemoglobin  
HbA1 =        ____________________________  x 4.61 (Assay factor)     
Absorbance of Total Haemoglobin  
 
 
Values of HbA1cwas obtained from  values of HbA1 using Table No.21. 
Estimation of blood urea, serum creatinine and plasma glucose was done 
using urease method, Alkaline pictrate method and GOD / POD method 
respectively.  
 53
RESULTS 
 The levels of the analysed biochemical parameters namely fasting 
plasma glucose, HbA1C, Sr.Mg, Bl.urea, Sr.Creatinine, in 120 human subjects 
are tabulated in Table No.1 to 6 depending on the study group to which they 
belong. 
 Table No.1 enumerates the levels of the biochemical parameters in the 
control group formed by the 20 apparently healthy subjects. The first 10 
subjects in the above table are apparently healthy males while the latter 10 
subjects are apparently healthy females. The levels in apparently healthy male 
and apparently healthy female of the above table have been seggregated into  
tables namely 1a and 1b respectively.  
Table 2 enumerates the biochemical parameter of Type 2 diabetics 
mellitus patients without any complications.  
Table 3 enumerates biochemical parameters of Type 2 diabetes mellitus 
patients with angiogram proved coronary atherosclerosis. 
Table 4 enumerates, biochemical parameters of Type 2 DM patients 
with Peripheral vascular disease who presented as foot ulcer. 
Table 5 and 6 enumerates and biochemical parameters of Type 2 DM 
patient with retinopathy and nephropathy respectively. 
The mean and SD for each parameter of the above tables which have 
been calculated are also shown in the respective tables. These mean values of 
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the parameters in the different groups are also depicted as histrogram in 
diagram No.1 to 5. 
In order to find out whether the mean levels of the biochemical 
parameters in the entire control group (Table 1) can be utilised as the reference 
range for the study or considerable weightage has to be given for sex, the mean 
levels and the S.D. of the biochemical parameters in apparently health males 
and females (Table 1a and 1b) are compared with each other in Table No.7 
Statistical significance has been ascertained for each parameter in the Table-7. 
Since none of the parameter of the study in the above table show any 
significant variation between sexes, the reference range selected for each 
parameter is the respective mean and S.D. obtained in Table 1 as in this table 
level of the parameters of all the control subjects irrespective of sex have been 
pooled together. 
To find out statistically how far the levels of the biochemical parameters 
varied from the reference range in the different study groups, the mean and 
S.D. of each parameters in the different study groups. (Category 2-6) are 
compared with the obtained reference range in Table No.8 to 12. 
Table 8 : Comparison of the levels of biochemical parameters in 
uncomplicated type 2 DM patients with that of reference 
range.  
Table 9 : Comparison of the levels of biochemical parameters in 
type 2 DM patients with angiographically proved 
Coronary atherosclerosis (CAS) with that of reference 
range. 
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Table 10 : Comparison of the levels of biochemical parameters in 
type 2 DM patients with peripheral vascular disease 
presenting with foot ulcer with that of reference range. 
Table 11 : Comparison of the levels of biochemical parameters in 
type 2 DM patients with retinopathy with that of reference 
range. 
Table 12 : Comparison of the levels of biochemical parameters in 
type 2 DM patients with nephropathy with that of 
reference range. 
To analyse how far the levels of biochemical parameters varied in the 
various complications of Type 2 diabetes mellitus from that of in the 
uncomplicated DM, the mean and S.D.  of  various biochemical parameters in 
each of the former group is compared with that of the latter in Table No.13 to 
16 
 Table 13 : Comparison of the levels of biochemical 
parameters in type 2 DM patient with CAS. with 
that of uncomplicated group. 
 Table 14 :  Comparison of the levels of biochemical 
parameters in type 2 DM patient with PVD 
presenting with foot ulcer with that of 
uncomplicated group. 
Table 15 : Comparison of the levels of biochemical 
parameters in type 2 DM patient with retinopathy 
with that of uncomplicated group. 
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Table 16 : Comparison of the levels of biochemical parameters in 
type 2 DM patient with nephropathy with that of 
uncomplicated group. 
The statistical significance between the levels of various biochemical 
parameter in all the comparison table was ascertained from the calculated "P" 
value which was arrived using the `student t test' 
 To determine how far Sr Mg varied with the severity of diabetes 
mellitus and the degree of control of the disease, Sr Mg. levels in the subjects, 
irrespective of grouping and as well with regard to grouping have been 
correlated with that of FPG and HbA1C of the respective subjects in table No. 
17 and 18. Karl-Person correlation coefficient between Sr.Mg and FPG in table 
number 17 shows negative and fair correlation in all the groups except in group 
consist of type 2 DM with retinopathy. 
 The table 18 shows the Karl-Pearson correlation coefficient between 
Sr.Mg. & HbA1C arrived in the different groups & which have been 
seggregated into two subdivisions comprising of HbA1C values less that 6.1% 
and equal or more than 6.1%.  
This correlation between Sr.Mg.& FPG is also shown as scatter diagram 
in diagram No. 6 to 12.  Similarly  correlation between Sr.Mg. and HbA1C in 
the  entire 120 subjects irrespective of the grouping as well as in each of the 
study group is depicted as the  scatter diagram in diagram No. 13 - 19.  
 To find out the cut off values for the Sr.Mg between control group and 
type 2 DM without any complication, line diagram is plotted in graph No.1. 
Graph No.2 shows the line diagram for Sr.Mg between uncomplicated type 2 
DM and Type 2 DM with macrovascular complications namely CAS, PVD. (10 
patients from each group of macrovascular complication are selected).  
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DISCUSSION 
 Discussion on the result is begun by considering the validity of the 
reference range obtained for the biochemical parameters of the study, which are 
2.09 ± 0.30 mg/dl  for Sr.Mg; 85.06 ± 15.82 mg/dl for fasting plasma glucose; 
20.90 ± 5.31 mg/dl for blood urea  0.93 ± 0.22 mg/dl for Sr. creatinine; 5.46 ± 
0.33% for HbA1C. 
 Serum Mg level of 2.09 ± 0.30 mg/dl in the study correlates well with 
that of Maclean R, whose reference range is 1.7-2.4 mg / dl.1 This level is also 
within the reference range of 1.7 - 2.5 mg/dl quoted by Pennel C Painter.2 
Scrutinization of the reference range of other parameters of the study 
shows that they are well within the reference range quoted in standard text 
books and that of the kit methodology undertaken for their analysis. 
Hence the acceptance of the mean values of the biochemical parameters  
obtained  from the control group consisting of both males and famales, as 
reference range for the respective parameters is valid. 
*** 
Comparison of levels of various biochemical parameters of 
uncomplicated Type 2 DM with that of R.R. (Table 8) reveals that in 
uncomplicated Type 2 DM fasting plasma glucose is increased to HS levels 
(p=.000), HbA1C is increased to MS level (p=.002) and Sr. Mg level is 
decreased to MS level (p=.001) 
The HS increase of fasting plasma glucose (FPG) is an expected finding 
in view of the disease involved in the former group. 
MS higher value of HbA1C may be attributed to the poor compliance of 
the patient in the study group. 
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 The decrease of Sr.Mg to MS levels in uncomplicated Type 2DM can be 
either a sequelae of Type 2 DM or can be an etiological factor of the disease as 
elaborated below : 
1.  Mg is an important factor for insulin secretion and insulin action. 
Mg depletion per se has been reported to impair insulin secretion 
as well as to reduce insulin sensitivity of the peripheral tissue. 
2. The osmatic diuresis in Type 2 DM patients which is associated 
with loss of Mg in the urine leads to lower Mg value in the serum 
of such patients. 
Mg impairing insulin secretion turns out to be an etiological cause, 
whereas osmotic diuresis depleting Mg turns out to be a sequelae of the 
disease. 
*** 
Comparison of the levels of various biochemical parameters of Type 2 
DM with macrovascular complications namely coronary atherosclerosis (CAS) 
and peripheral vascular disease (PVD) with that of  reference range in Table 
No.9 and 10 reveals that while HbA1c is  increased to HS levels in type 2 DM 
with CAS ( p = .000), it increases only to significant levels in type 2 DM with 
PVD (p=.036). 
On the other hand, Sr.Mg is lowered to MS levels (p=.001) from the R.R 
in both the groups. 
As HbA1c  signifies only the control of disease in the 3 months prior to 
the time of assessment, the elevation of HbA1c is different in the two groups 
Probably the subjects in type 2 DM with PVD might have adhered more to the 
treatment than those belonging to the group of CAS. 
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As complications of type 2 DM normally sets only is long standing DM, 
the moderate decrease of Sr.Mg in both the groups of macrovascular 
complication is acceptable, since it's prevalence itself reveals the chronicity of 
the disease. 
Absence of any statistically significant increase in fasting  plasma 
glucose (FPG), inspite of HbA1c showing statistical increase in macrovacular 
complication may be due to the temporary control of the glucose level on the 
day of assessment. 
*** 
Similarly when the levels of various biochemical parameters of type 2 
DM with microvascular complications namely diabetic retinopathy and diabetic 
nephropathy is compared with that of the R.R, it is observed that HbA1c values 
are statistically not different in type 2 DM with microvascular complication 
from the R.R. (p= 1.000 & = 0.199 in Table no 11 and 12 respectively). 
On the other hand, MS decrease of Sr.Mg (p=0.001) is found both in 
Type 2 DM with retinopathy and in type 2 DM with nephropathy. 
Absence of significant increase of HbA1c in type 2 DM with 
microvascular complications, and significant increase of HbA1c in type 2 DM 
with macrovascular complications may be due to difference in following the 
treatment schedule by the subjects in different subsets. 
The M.S. lower value of Sr.Mg in patients with type 2 DM with 
microvascular complication from the R.R. may once again be attributed to the 
chronicity of the disease. 
Inspite of the normal Bl.urea level of 31.15 mg/dl in Type 2 DM with 
nephropathy, a HS increase has been obtained statistically for this parameter in 
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this complication on comparison with the R.R. As 31.15 mg/dl level of Bl.urea 
obtained in this complication is still within universally accepted R.R, it can be 
presumed that the subjects selected in this group might have had only mild 
nephropathy, which is also emphasized by the fact that Sr.creatinine level is 
also normal in this group. Moreover as the subjects of this group were 
inpatients of the  hospital and were on strict diet regime with minimal protein 
intake, the normal level of blood urea is acceptable for this group. 
*** 
When the levels of various biochemical parameters in Type 2 DM with 
different complication are compared with the respective levels in 
uncomplicated type 2 DM in Table No.13,14,15,16, it is seen that Sr.Mg level 
in macrovascular complication is significantly decreased from that in 
uncomplicated type 2 DM (p=0.05 in both macrovascular complication), where 
as in type 2 DM with microvascular complication the difference does not  exist 
(p=1.000 in both microvascular complication). This finding reveals an increase 
of the intensity of hypomagnesemia in only macrovascular complications of 
Type 2 DM to that of uncomplicated Type 2 DM. 
As any macrovascular complication of DM is basically due to the 
development of atherosclerosis, it may be presumed that the further increase of  
intensity of hypomagnesemia observed in these complications may add up to 
the several etiological causes of altherosclerosis. 
The theories attributing to the development of atherosclerosis in DM due 
to hypomagnesemia is given below:- 
1. Mg is an antioxidant. Lowering of Mg level further in Type 2 
DM patients puts such patients at higher risk of developing oxidized LDL 
which is very atherogenic and leads to higher degree of atherosclerosis. 
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2. Further, Mg depletion leads to greater increase than that in 
uncomplicated Type 2 DM, of triacylglycerol and total cholesterol in the body 
due to decreased lipoprotein lipase activity as well as decreased lecithin 
cholesterol acyl transferase activity147. 
It is a well known fact that increased level of the triacyglycerol and total 
cholesterol are atherogenic and greater their level, higher is the degree of 
atherogenesis. 
The absence of any statistical difference in Sr.Mg level in Type 2 DM 
with retinopathy or nephropathy from the level in uncomplicated type 2 DM 
reveals that increase of the degree of hypomagnesemia is not a contributory 
factor for the development of these complication, which correlates well with 
the finding of Sheehan J.P. who had found that there is no role of further 
deficiency of Mg for the development of microvascular complications in type 2 
DM150. 
The  above finding is apt when we consider the pathogenesis of diabetic 
retinopathy and nephropathy as discussed previously on page 32 to 35.  As per 
the review on these pages, in the pathogenesis of diabetic retinopathy and 
diabetic nephropathy Mg role has not been substantiated, moreover only polyol 
pathway, AGE and increased activity of protein kinase C are found to lead  to 
the development of diabetic retinopathy; While in diabetic nephropathy it is  
hyperglycemia, AGE, polyol pathway, proteinuria and hypertension. 
Absence of further increase in the intensity of hypomagnesemia in 
neprhopathy can also be explained on the following lines. 
Nephropathy in various stages have various effects on Sr.Mg level.In 
early stages of nephropathy there is retention of magnesium while in advanced 
stages of nephropathy there is loss of Mg via urine. 
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As the subjects of type 2 DM with nephropathy selected in this study 
were all having early nephropathy, retention of Mg may be the reason for 
absence of hypomagnesemia in this group of patients. 
So staging of nephropathy, which has not been done in this study is 
essential before Sr.Mg role is implicated in this complication. 
FPG is lowered in all the diabetic groups with complication leading to 
statistically significant lowering of the parameter in all the above groups, 
except in CAS which can be attributed to the wide S.D obtained for this 
parameter in this group. Provided wide S.D. was not present in CAS, this group 
also would have shown S.S. decrease. The degree of statistically significance 
for FPG however varies between the groups.  
Therefore it is inferred that there is statistically significant lowering of 
FPG in all the complication of Type 2 DM analysed, from it's level in 
uncomplicated Type 2 DM. 
This lowering of FPG in diabetic complication can be attributed to the  
fact that these patients are more cautious in controlling the plasma glucose 
level by strictly adhering to the treatment schedule than those with 
uncomplicated Type 2 DM; for the former, patients would have started 
realizing the seriousness of the disease once the complication sets in.  
*** 
As hypomagnesemia has been found to be associated with Type 2 DM 
and a further statistical lowering of its level is seen in Type 2 DM with 
macrovascular complications; attempt has been made to arrive at a cut off level 
for Sr.Mg between control and uncomplicated Type 2 DM and that of the latter 
with macrovascular complication of Type 2 DM. For this purpose line graph 
have been drawn in Graph No.1, with the level of Mg in control and in patients 
of uncomplicated DM. Various cut off levels have been selected and their 
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calculated sensitivity /  specificity,  PPV  /  MVP  are  shown  in  Table No.19.  
1.9 mg/dl of Sr.Mg which has a 80% sensitivity, 80% specificity, 80%  positive 
predictive value 80% negative predictive value is found to be the most 
appropriate cut off between control and patients of uncomplicated DM i.e. 
levels of 1.9 mg/dl of Sr.Mg and below indicate Type 2 DM. 
Similarly, graph has been plotted with levels in uncomplicated Type 2 
DM and macrovascular complications of Type 2 DM in Graph No.2. The most 
appropriate cut off level between these entities as  shown  in  Table No.20  is  
1.5 mg/dl of Mg. i.e. level of 1.5 mg/dl and below of Sr.Mg indicate the 
presence of macrovascular complication namely coronary atherosclerosis and 
peripheral vascular disease in Type 2 DM. The above two cut off levels are 
also shown in the respective graphs. 
When the Karl Pearson correlation coefficient between Sr.Mg and FPG 
(Table No.17) is analysed it is seen that there is a negative correlation between 
these two parameters in controls, uncomplicated type 2 DM, all groups of 
complications of Type 2 DM, and as well in the overall group. This negative 
correlation is fair in all the groups except DM with retinopathy which is poor. 
Negative correlation between Sr.Mg. and FPG may be because of loss of Mg in 
the urine via glycosuria in presence of hyperglycemia. So higher plasma 
glucose is associated with lower Mg in the serum. 
Similarly, when the Karl - Pearson correlation coefficient between 
Sr.Mg and HbA1c (both in 4.8 to 6.1 and >6.1 groups - Table No.18) is 
analysed it is seen that there in negative correlation between these two 
parameters in controls, uncomplicated type 2 DM, all groups of complications 
of Type 2 DM, and as well in the overall group. This negative correlation is fair 
to very good in various groups. Again negative correlation between Sr.Mg and 
HbA1c can be attributed to loss of Mg via urine due to osmotic diuresis in 
presence of uncontrolled hyperglycemia. 
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CONCLUSION 
 From the analysis of the results obtained, in controls, Type 2 DM 
patients without complication and Type 2 DM with various macro and 
microvascular complication selected for the study, the following conclusions 
are made : 
1. The reference range for S.Magnesium is 1.79 mg/dl to 2.39 mg/dl. 
2. There is definite hypomagnesemia in Type 2 DM patients irrespective of 
the presence or absence  of complication of Type 2 DM, when compared 
to control group. 
3. Sr.Mg is statistically lower in macrovascular complications of Type 2 
DM namely coronary atherosclerosis and PVD to that of its level in 
uncomplicated Type 2 DM. 
4. The statistical lowering of Sr.Mg is absent between microvascular 
complication of Type 2 DM namely retinopathy and nephropathy and 
uncomplicated Type 2 DM. 
5. Sr.Mg and HbA1c of <6.1% and >6.1% show negative correlation 
varying from fair to very good correlation in all the groups analysed. 
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6. Sr.Mg and FPG shows negative and fair correlation between all the 
groups except in Type 2 DM with retinopathy, where it shows negative 
and poor correlation. 
7. 1.9 mg/dl is the cut off level for Sr.Mg between control group and Type 
2 DM without any complication. 
8. 1.5 mg/dl is the cut off level  for Sr.Mg between Type 2 DM without 
complication and Type 2 DM with macrovascular complications namely 
CAS and PVD. 
*** 
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SCOPE FOR FURTHER STUDY 
 
1. Study can be done on the evaluation of Sr.Mg in Type 2 DM and it's 
various complication for larger number of patients in each group. 
2. Other complications of Type 2 DM namely cerebrovascular accidents, 
neuropathy can also be included in study. 
3. Evaluation of Sr.Mg in Diabetic nephropathy can be done according to 
stage of the nephropathy and also associated urine analysis for Sr.Mg 
can be done to evaluate the amount of Sr.Mg loss in urine. 
4. Study can be extended to Type I  DM. 
*** 
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ABBREVIATIONS 
 
 AGE  - Advanced glycosylation end product 
 
 ADA  - American diabetic association 
 
 CVD  - Cardivascular disease 
 
 CREAT - Creatinine 
 
 DCCT  - Diabetes control and complication trial 
 
 DAG  - Diacylglyserol 
 
 DM  - Diabetes mellitus 
 
 ECM  - Extracellular matrix 
 
 FPG  - Fasting plasma glucose 
 
 GLUT  - Glucose uptake and Transport 
 
 GAPDH - Glyseraldehyde 3 - phosphate dehydrogenase 
 
 HbA1c - Glycosylated hemoglobin 
 
 IRS  - Insulin receptor substrate 
 
 IL-6  - Interleukin - 6 
 
 IHD  - Ischaemic heart disease 
 
 NEFA  - Non esterified fatty acid 
 
 Mg  - Magnesium 
 
 PKC  - Protein kinase - C 
 
 PVD  - Peripheral vascular disease 
 
 ROS  - Reactive oxygen species 
 
 RDA  - Recommended daily allowance 
 
 SOCS  - Suppressor of cytokine signalling 
 
 TNF - α  - Tissue necrosis factor - α 
 
 UKPDS - United Kingdom prospective diabetic study 
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Courtesy : Text book of Diabetes 2. 3rd Ed., Blackwell Publishing 
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CORRELATION BETWEEN SERUM MAGNESIUM & FPG
IN OVERALL GROUP
FPG
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CORRELATION BETWEEN SERUM MAGNESIUM & FPG IN NORMAL
FPG
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CORRELATION BETWEEN SERUM MAGNESIUM &  FPG
 DM without complication
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CORRELATION BETWEEN SERUM MAGNESIUM & FPG
in Type II DM with Coronary Atherosclerosis
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CORRELATION BETWEEN SERUM MAGNESIUM & FPG
in Type II DM with PVD
FPG
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CORRELATION BETWEEN SERUM MEGNESIUM & FPG
in Type II DM with retinopathy
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CORRELATION BETWEEN SERUM MAGNESIUM & FPG
in Type II DM with Nephropathy
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Correlation between Serum Magnesium and HbA1c(Overall)
HbA1c(% of total Hb) 
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Correlation between Serum Magnesium and HbA1c(Control group) 
HbA1c(% of total Hb)
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Correlation between Serum magnesium and HbA1c
(DM type 2 with Coronary Atherosclerosis )
HbA1c(% of total HB)
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Correlation between Serum Magnesium and HbA1c
(DM Type 2 without complication)
HbA1c(% of total Hb)
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Correlation between Serum Magnesium and HbA1c
( DM Type 2 with Foot Ulcer)
HbA1c(% of total Hb)
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Correlation between Serum Magnesium and HbA1c
( DM Type 2 with Nephropathy)
HbA1c(% of total Hb)
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Correlation between Serum magnesium and HbA1c
(DM Type 2 with Retinopathy)
HbA1c(% of total Hb)
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